
News|Articles|May 1, 2002
Outcomes in ACS: GP IIb/IIIa inhibitor plus LMWH superior to GPs plus unfractionated heparin
Atlanta-The low-molecular-weight heparin enoxaparin improves outcomes compared with currently recommended therapy in patients with non-ST-segment elevation acute coronary syndromes (ACS) who are being treated with a glycoprotein (GP) IIb/IIIa inhibitor, said Shaun Goodman, MD.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Health Begins at Home: Why Housing Has Become a Strategic Priority for Managed Care
2
A conversation with Dolores Malaspina, M.D., about the generational impact of Holocaust trauma on schizophrenia risk
3
Intervention boosts connected insulin pen adoption among minorities with Type 1 diabetes
4
Could uveitis in patients with melanoma being treated with immune checkpoint inhibitors be a good thing?
5


























